CRBUNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Caribou Biosciences, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.46−0.01 (-1.26%)

Close on Oct 19, 2026

Market cap: $46.86M
P/E (TTM): –
Dividend yield: –

Caribou Biosciences, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Revenue	11	9.99	34	14	9.60	12	5.79
Research & Development	109	130	112	82	52	34	24
General & Administrative	38	46	38	38	24	14	16
Operating Expenses	160	177	151	120	77	48	40
Operating Income	-148	-167	-116	-106	-67	-36	-34
Interest Expense	–	–	–	–	0.01	0.02	0.00
Interest & Investment Income	–	–	–	–	0.15	0.24	1.05
Other Non-Operating Income	-0.33	18	14	7.05	0.38	0.00	3.34
Merger & Restructuring Charges	14	–	–	–	–	–	–
Asset Impairment Charges	12	0	–	–	–	–	–
Gain (Loss) on Investments	-0.10	-0.11	-0.01	-0.13	0	-0.73	2.29
Gain (Loss) on Sale of Assets	0.03	0.01	0.03	0	0.00	-0.07	0.00
Pretax Income	-149	-149	-102	-99	-67	-36	-31
Income Tax Expense	-0.55	-0.01	0.19	0.07	0.32	-1.82	-7.54
Net Income incl. Noncontrolling Interests	-148	-149	-102	-99	-67	-34	-23
Net Income	-148	-149	-102	-99	-67	-34	-23
EPS (Basic)(per share)	-1.59	-1.65	-1.38	-1.64	-2.11	-4.01	-2.80
EPS (Diluted)(per share)	-1.59	-1.65	-1.38	-1.64	-2.11	-4.01	-2.80
Shares Outstanding (Basic, Weighted)(shares)	93	90	74	61	32	8.55	8.37
Shares Outstanding (Diluted, Weighted)(shares)	93	90	74	61	32	8.55	8.37
EBITDA	-145	-163	-113	-105	-66	-35	-34

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -1090.9%
Net margin: -1030.4%
Return on equity, FY2025: -79.0%

Financial strength

Current ratio: 6.49
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 145.7%

Valuation

P/E ratio: –
Price to sales: 4.67
Price to book: 0.48
Dividend yield: –